HSCS
HeartSciences Inc.
There isn't enough reported data to score HSCS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
HSCS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
HSCS's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HSCS PE Valuation
HSCS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HSCS Forward outlook
There aren't enough analyst estimates for HSCS to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HSCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.76 | +$5.52 |
| Q2 2026 | -$3.48 | +$5.86 |
| Q1 2024 | -$46.00 | +$84.03 |
| Q4 2023 | -$59.00 | +$92.30 |
| Q3 2023 | -$65.00 | +$95.53 |
| Q2 2023 | -$80.00 | +$67.67 |
| Q1 2023 | -$130.03 | -$20.69 |
HSCS is still losing money, but far less than before: $2.76 per share over the past year, against $160.53 at its worst in mid-2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HSCS on earnings quality, reporting a profit while its opponent remains loss making.
HSCS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.1K | +11% |
| Q1 2024 | $14.7K | +654% |
| Q1 2023 | $2K | -29% |
| Q3 2022 | $3.2K | -57% |
| Q2 2022 | $4.1K | -72% |
HSCS's revenue is recovering but still below its 2021 peak: $2,100 last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -139957% | -41319 points |
| Q4 2025 | -85713% | N/A |
| Q3 2025 | -98638% | N/A |
| Q1 2024 | -10377% | +56767 points |
| Q4 2023 | -40255% | N/A |
| Q1 2023 | -67144% | -26987 points |
| Q3 2022 | -44691% | -35679 points |
| Q2 2022 | -47670% | -42410 points |
HSCS's operating margin was −139957% last quarter, down 99702 points from the same quarter a year ago, near the bottom of its range since 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HSCS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HSCS on profitability, with a higher operating margin.
HSCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.3M | +$634.5K |
| Q2 2026 | -$1.7M | -$85.9K |
| Q1 2026 | -$1.5M | +$167K |
| Q3 2025 | -$2M | +$65.4K |
| Q2 2025 | -$1.6M | -$5.5K |
| Q1 2025 | -$1.6M | +$530.1K |
| Q3 2024 | -$2M | -$609.5K |
| Q2 2024 | -$1.6M | +$284.1K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with HSCS at down 11%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
HSCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +507K shares |
| 1 year | +272% | +2.7M shares |
| 3 years | +6399% | +3.6M shares |
HSCS has 4M diluted shares, up 272% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HSCS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HSCS Net Leverage
HSCS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HSCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 26.7 | Neutral |
HSCS's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HSCS PE vs Healthcare Sector
HSCS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HSCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.35 | 33% below |
| 20 week MA | $3.09 | 27% below |
| 50 week MA | $2.73 | 17% below |
| 100 week MA | $3.07 | 26% below |
| 200 week MA | $24.3 | 91% below |
HSCS is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HSCS on trend strength, trading above more of its moving averages.
HSCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $208.0 | $89.0 | -57% |
| 2023 | $89.0 | $17.1 | -81% |
| 2024 | $17.1 | $3.81 | -78% |
| 2025 | $3.81 | $2.85 | -25% |
| 2026 YTD | $2.85 | $2.26 | -21% |
HSCS has finished every year since 2022 lower, and it's down 21% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HSCS on returns for 2026, with the stronger performance.